SM
VRTX icon

Sabby Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sabby Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,315
Closed -$861K – 184
2018
Q1 		$861K Buy
1,315
+396
+43% +$64.7K 0.1% 73
2017
Q4 		$13.8M Sell
919
-1,946
-68% -$288K 1.25% 15
2017
Q3 		$43.6M Sell
2,865
-1,688
-37% -$254K 2.85% 10
2017
Q2 		$58.7M Buy
4,553
+3,177
+231% +$382K 3.84% 7
2017
Q1 		$15M Buy
1,376
+306
+29% +$26.9K 0.81% 21
2016
Q4 		$7.88M Sell
1,070
-885
-45% -$72K 0.46% 36
2016
Q3 		$17.1M Buy
1,955
+1,346
+221% +$127K 0.64% 30
2016
Q2 		$5.24M Buy
609
+59
+11% +$5.1K 0.27% 55
2016
Q1 		$4.37M Buy
550
+209
+61% +$18.9K 0.22% 48
2015
Q4 		$4.29M Hold
341
– – 0.24% 69
2015
Q3 		$3.55M Buy
341
+206
+153% +$26.5K 0.15% 107
2015
Q2 		$1.67M Sell
135
-99
-42% -$12.5K 0.06% 184
2015
Q1 		$2.76M Sell
234
-3,647
-94% -$437K 0.11% 118
2014
Q4 		$46.1M Sell
3,881
-18,788
-83% -$2.12M 1.46% 13
2014
Q3 		$255M Sell
22,669
-7,167
-24% -$682K 9.78% 3
2014
Q2 		$282M Buy
29,836
+5,836
+24% +$409K 12.11% 2
2014
Q1 		$170M Sell
24,000
-2,661
-10% -$211K 9.52% 1
2013
Q4 		$198M Buy
26,661
+1,771
+7% +$123K 12.63% 1
2013
Q3 		$189M Buy
24,890
+1,825
+8% +$145K 12.26% 1
2013
Q2 		$184M Buy
+23,065
New +$1.7M 12.3% 1

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sabby Management's VRTX Position: Q2 2016 in Review

Sabby Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 23,320 shares — an estimated $2.02M sold.

Sabby Management first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $25.5M in Q3 2013. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

  • Sabby Management reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Sabby Management sold 23,320 Vertex Pharmaceuticals shares in Q2 2016, an estimated $2.02M.
  • Sabby Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Sabby Management's Vertex Pharmaceuticals position peaked at $25.5M in Q3 2013.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.